Trial reportThe New England journal of medicine2010
Dietary intervention in infancy and later signs of beta-cell autoimmunity.
Trial report in The New England journal of medicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00570102 (Trial to Reduce IDDM in the Genetically at Risk), which is not on this map. Cited by 122 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Trial to Reduce IDDM in the Genetically at Risk (TRIGR): the Pilot Study
Who cites it
122 citing papers in PubMed, 3 syntheses or guidelines pooled it, 9 citations in OpenAlex.
- Infant formulas containing hydrolysed protein for prevention of allergic disease.The Cochrane database of systematic reviews · 2018Pooled it
- WITHDRAWN: Infant formulas containing hydrolysed protein for prevention of allergic disease and food allergy.The Cochrane database of systematic reviews · 2017Pooled it
- Infant formulas containing hydrolysed protein for prevention of allergic disease and food allergy.The Cochrane database of systematic reviews · 2017Pooled it
- Trial
- Associations Between Serum Fatty Acids and Immunological Markers in Children Developing Islet Autoimmunity-The TRIGR Nested Case-Control Study.Frontiers in immunology · 2022Trial
- Association between family history, early growth and the risk of beta cell autoimmunity in children at risk for type 1 diabetes.Diabetologia · 2021Trial
- Probiotic intervention in infancy is not associated with development of beta cell autoimmunity and type 1 diabetes.Diabetologia · 2018Trial
- Trial
- Characterization of human organ donors testing positive for type 1 diabetes-associated autoantibodies.Clinical and experimental immunology · 2015Trial
- Trial
- Environmental determinants of islet autoimmunity (ENDIA): a pregnancy to early life cohort study in children at-risk of type 1 diabetes.BMC pediatrics · 2013Trial
- Primary dietary intervention study to reduce the risk of islet autoimmunity in children at increased risk for type 1 diabetes: the BABYDIET study.Diabetes care · 2011Trial
- Diet, gut microbiome, and type 1 diabetes: from risk to translational opportunity.Gut microbes · 2026Review
- Coxsackievirus B Infections Are Associated With the Risk of Islet Autoimmunity in Children With Strong Genetic Susceptibility to Type 1 Diabetes-Results From the TRIGR Divia Study.Diabetes/metabolism research and reviews · 2026Article
- Safety and Immunogenicity of a Vaccine Against Coxsackieviruses B (PRV-101)-Follow-up of the First-in-Human Phase 1 Trial.Open forum infectious diseases · 2026Article
- Evolving epigenomics of immune cells at single-nucleus resolution in children en route to type 1 diabetes.Nature communications · 2026Article
- Article
- Characteristics of Type 1 Diabetes Among Patients Carrying the Protective HLA-DQB1*06:02 Allele.HLA · 2024Observational
- A Review of Stage 0 Biomarkers in Type 1 Diabetes: The Holy Grail of Early Detection and Prevention?Journal of personalized medicine · 2024Review
- Breastfeeding decreases the risk of developing psoriasis through to early adulthood.The British journal of dermatology · 2024Article
62 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
14 authors at 1 institution in 1 country.
Funding
Abstract
backgroundEarly exposure to complex dietary proteins may increase the risk of beta-cell autoimmunity and type 1 diabetes in children with genetic susceptibility. We tested the hypothesis that supplementing breast milk with highly hydrolyzed milk formula would decrease the cumulative incidence of diabetes-associated autoantibodies in such children.
methodsIn this double-blind, randomized trial, we assigned 230 infants with HLA-conferred susceptibility to type 1 diabetes and at least one family member with type 1 diabetes to receive either a casein hydrolysate formula or a conventional, cow's-milk-based formula (control) whenever breast milk was not available during the first 6 to 8 months of life. Autoantibodies to insulin, glutamic acid decarboxylase (GAD), the insulinoma-associated 2 molecule (IA-2), and zinc transporter 8 were analyzed with the use of radiobinding assays, and islet-cell antibodies were analyzed with the use of immunofluorescence, during a median observation period of 10 years (mean, 7.5). The children were monitored for incident type 1 diabetes until they were 10 years of age.
resultsThe unadjusted hazard ratio for positivity for one or more autoantibodies in the casein hydrolysate group, as compared with the control group, was 0.54 (95% confidence interval [CI], 0.29 to 0.95), and the hazard ratio adjusted for an observed difference in the duration of exposure to the study formula was 0.51 (95% CI, 0.28 to 0.91). The unadjusted hazard ratio for positivity for two or more autoantibodies was 0.52 (95% CI, 0.21 to 1.17), and the adjusted hazard ratio was 0.47 (95% CI, 0.19 to 1.07). The rate of reported adverse events was similar in the two groups.
conclusionsDietary intervention during infancy appears to have a long-lasting effect on markers of beta-cell autoimmunity--markers that may reflect an autoimmune process leading to type 1 diabetes. (ClinicalTrials.gov number, NCT00570102.).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.